-
Dementia cases could triple by 2050 if countries do not address the risk factors
According to a study published in The Lancet Public Health, the number of people with dementia could triple by 2050. This study is conducted by an international research team with the participation of Dr. Ai Koyanagi and Dr. Jacob Louis of Epidemiology of Mental Disorders and Aging from IRSJD.
-
Researchers discover a key factor that predicts COVID-19 disease severity
A study led by Drs. Laia Alsina and Iolanda Jordan from the IRSJD evidences a key factor that predicts the severity of COVID-19: an alteration of the first immune response to SARS-CoV-2 infection, in key molecules in the anti-infective response. The study has been published in open access in the journal iScience.
-
Mitochondria-lysosome contacts: a new cell phenotype in neurogenetic diseases
The Neurogenetics and Molecular Medicine research group of the Institut de Recerca Sant Joan de Déu (IRSJD), in collaboration with the Neuromuscular Pathology Unit of the SJD Barcelona Children's Hospital (HSJD), has studied the pathophysiology of mitochondrial dynamics and mitochondrial- lysosome contacts in cells from patients with neurogenetic diseases. The article has been published in the journal Frontiers in Neuroscience.
-
61% of people with early psychotic episodes have experienced childhood trauma
A study published in the Journal of Psychiatric Research and conducted by Regina Vila, a predoctoral researcher, and led by Dr. Judith Usall, co-coordinator of the Ethiopathogenesis and Treatment of Severe Mental Disorders (MERITT) group at the Institut de Recerca Sant Joan de Déu, analyzes factors and sociodemographic variables that may influence the onset and evolution of a first episode psychotic.
-
A nanomedicine to improve treatment of Ewing sarcoma
A team led by Dr. Ángel Montero Carcaboso at the Institut de Recerca Sant Joan de Déu (IRSJD) shows that albumin nanoparticles improve the biopharmaceutical properties of paclitaxel in a rare type of tumor called Ewing sarcoma. The publication is highlighted on today's cover of the Journal of Controlled Release.
-
Science4Pandemics: A European Gamification Project to Better Prepare Young People for Future Pandemics
Despite the many advances in the global fight against infectious diseases and the millions of lives saved by vaccines and other preventive and therapeutic methods, infections remain a major threat to humanity.
-
Psychosocial and psychological interventions reduce relapse risk in schizophrenia
Dr. Helena García-Mieres from the IRSJD has collaborated in an international study, led by researchers from the Technical University of Munich and the University of Catania, which has analyzed the results of different studies on relapses in schizophrenia to check the efficacy of psychological and psychosocial interventions for its relapse prevention.
-
Josep Maria Haro and Ai Koyanagi among the most influential researchers worldwide
According to the ranking of the innovation company Clarivate Analytics, Dr. Ai Koyanagi and Dr. Josep Maria Haro are among the hundred most prominent experts who work in the Spanish State and lead projects with an international impact.
-
Gate2Brain receives funding from ”la Caixa” Foundation to accelerate its transfer to the market and society
Gate2Brain, a spin-off of Sant Joan de Déu (SJD), Institute for Research in Biomedicine (IRB) Barcelona and University of Barcelona (UB) will develop a new drug using a shuttle peptide that crosses the blood-brain barrier (BBB) to improve treatments for pediatric brain cancer.
